Starling Oncology, Inc. (STLNW) stock
STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN
$0.03+0.00 (+10.87%)
Close on Oct 30, 2026Market cap $665.51MP/E –Yield –
Starling Oncology profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Starling Oncology's profit margin for the twelve months ending Jun 30, 2026 was -6.2%. For fiscal 2025 it was -12.1%, against -16.4% the year before. The highest annual figure on record is 0.1% in fiscal 2022.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -12.1% | +4.4 |
| FY2024 | Dec 31, 2024 | -16.4% | +9.2 |
| FY2023 | Dec 31, 2023 | -25.6% | −25.7 |
| FY2022 | Dec 31, 2022 | 0.1% | +5.4 |
| FY2021 | Dec 31, 2021 | -5.4% | +2.3 |
| FY2020 | Dec 31, 2020 | -7.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -6.1% | +8.1 |
| Q1 FY2026 | Mar 31, 2026 | -1.7% | +17.1 |
| Q4 FY2025 | Dec 31, 2025 | -5.3% | +7.9 |
| Q3 FY2025 | Sep 30, 2025 | -12.1% | +4.0 |
| Q2 FY2025 | Jun 30, 2025 | -14.2% | +1.5 |
| Q1 FY2025 | Mar 31, 2025 | -18.8% | +2.3 |
| Q4 FY2024 | Dec 31, 2024 | -13.1% | +8.7 |
| Q3 FY2024 | Sep 30, 2024 | -16.1% | +5.1 |
| Q2 FY2024 | Jun 30, 2024 | -15.7% | +5.4 |
| Q1 FY2024 | Mar 31, 2024 | -21.0% | +18.4 |
| Q4 FY2023 | Dec 31, 2023 | -21.9% | −6.5 |
| Q3 FY2023 | Sep 30, 2023 | -21.2% | −17.1 |
| Q2 FY2023 | Jun 30, 2023 | -21.1% | −12.1 |
| Q1 FY2023 | Mar 31, 2023 | -39.4% | −74.3 |
| Q4 FY2022 | Dec 31, 2022 | -15.4% | +4.0 |
| Q3 FY2022 | Sep 30, 2022 | -4.1% | +1.6 |
| Q2 FY2022 | Jun 30, 2022 | -9.0% | −15.4 |
| Q1 FY2022 | Mar 31, 2022 | 35.0% | +37.0 |
| Q4 FY2021 | Dec 31, 2021 | -19.4% | – |
| Q3 FY2021 | Sep 30, 2021 | -5.7% | – |
| Q2 FY2021 | Jun 30, 2021 | 6.4% | – |
| Q1 FY2021 | Mar 31, 2021 | -2.1% | – |